Sensei Biotherapeutics (NASDAQ: SNSE) is an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer. Through the TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops highly selective therapeutics designed to disable checkpoints and other immunosuppressive signals in the tumor microenvironment to unleash existing T cells against tumors. The lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively only within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing other preclinical programs targeting multiple solid tumor indications.
Publicly Traded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):